engleski

Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma – where do we stand?

Almost 25% of all human cancers are located in the gastrointestinal tract (GIT), making it the dominant cancer- affected site. The reason for this could be constant GIT exposure to organ damage and chronic inflammation (1). Despite all medical breakthroughs, less than half of patients survive one year after the esophageal adenocarcinoma (EAC) diagnosis (2). Most malignancies, including most GIT malignancies, are preceded by precursor/premalignant lesions. Premalignant condition for EAC development is Barrett esophagus (BE), a disorder characterized by abnormal transformation of the squamous epithelium. BE is strongly associated with prolonged gastro-esophageal reflux of gastric and bile acids (1, 3, 4). Since patients with BE carry 30-40 times higher risk for EAC than general population, it is not surprising that in the last 10-20 years the research interest in BE has been growing

Barrett Esophagus ; Esophageal Neoplasms ; Adenocarcinoma

nije evidentirano